MaxCyte, Inc.
9713 Key West Ave., Suite 400
Rockville
Maryland
20850
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
216 articles about MaxCyte, Inc.
-
MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
10/28/2021
MaxCyte, Inc. today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.
-
MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021
10/25/2021
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), today announced that it will release financial results for the third quarter of 2021 after the U.S. market close on Wednesday, November 10th, 2021.
-
MaxCyte Set to Join Russell 2000® Index
9/17/2021
MaxCyte, Inc. today announced that it is set to join the Russell 3000® and Russell 2000® indices, effective after the U.S. market opens on September 20, 2021
-
MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections
9/13/2021
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced its financial results for its second quarter and six months ended June 30, 2021.
-
MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
9/2/2021
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021.
-
MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
8/9/2021
MaxCyte, Inc., a leading provider of cell-engineering platform technologies, announced the signing of a clinical and commercial license with Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines.
-
MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
7/30/2021
MaxCyte, Inc., a leading provider of cell-engineering platform technologies, announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share.
-
MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market - July 26, 2021
7/26/2021
MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announced the commencement of an underwritten offering of 12,000,000 shares of common stock at an expected offering price between $11.50 and $13.50 per share.
-
MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing
7/12/2021
MaxCyte, Inc. announced the public filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed dual listing of its shares of common stock on the Nasdaq Global Market under the symbol "MXCT." As part of the proposed Nasdaq dual listing, MaxCyte is planning a public offering of shares of its common stock in the United States.
-
Financial information in the Form S-1 registration statement and Change to Board of Directors
7/12/2021
MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.
-
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
-
MaxCyte Adds Two New Non-Executive Directors to Its Board
6/15/2021
MaxCyte, a leading provider of platform technologies for cell engineering, announced the appointment of Rekha Hemrajani and Yasir Al-Wakeel, BM BCh, to the company's board of directors as non-executive directors with immediate effect.
-
Celularity and MaxCyte Sign Strategic Platform License to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates
5/25/2021
Celularity to utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform to advance its off-the-shelf placental-derived allogeneic cellular therapies to treat hematological malignancies, solid tumors, and infectious and degenerative diseases
-
Proposed Dual-Listing on Nasdaq - May 14, 2021
5/14/2021
MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.
-
MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences
2/23/2021
MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows.
-
MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences - Nov 09, 2020
11/9/2020
MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that CEO Doug Doerfler will present an overview of the company at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, and at the Jefferies Virtual London Healthcare Conference on Thursday, November 19.
-
CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting
11/9/2020
MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that its subsidiary CARMA Cell Therapies will share results of a detailed phenotypic and functional characterization of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate, at the Society for Immunotherapy of Cancer's (SITC) 35th anniversary meeting
-
BioSpace Movers & Shakers, Oct. 16
10/16/2020
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers. -
MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments
10/13/2020
MaxCyte, Inc., a global cell-based therapies and life sciences company, announces a senior leadership promotion and appointments for two key vice president roles.
-
MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference
9/10/2020
MaxCyte, a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16 , 2020. Details are as follows: